Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326533 · ClinicalTrials.gov registry record · Phase 4
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT01326533 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 32 participants.
The verdict
NCT01326533, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.
Interventions
- OTHER Placebo
- DRUG hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326533
The ClinicalTrials.gov registry entry for NCT01326533 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01326533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01326533 about?
NCT01326533 is a clinical study titled "Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes". The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin secretion and glucose tolerance in subjects...
What is the current status of trial NCT01326533?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2011-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01326533?
The interventions under investigation include: Placebo (OTHER), hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01326533?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.